Lewis Tanya 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 1, 2021
Insider Transaction Report
Form 4
Lewis Tanya
EVP,Chief Reg.&Quality Officer
Transactions
- Award
Common Stock
2021-02-25+22,013→ 45,401 total - Award
Stock Option (right to buy)
2021-02-25+59,968→ 59,968 totalExercise: $14.56Exp: 2031-02-24→ Common Stock (59,968 underlying)
Footnotes (3)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.
- [F2]The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 19,245 RSUs previously reported in Table II, and 4,143 shares of common stock.
- [F3]This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.